In certain melanomas and colorectal cancers, inhibition of mutant BRAF suppresses oncogenic ERK signals but simultaneously relieves ERK-dependent negative feedback of RTKs, resulting in strong epidermal growth factor receptor (EGFR) stimulation, cell survival, and drug resistance9–12. The gene discussed is BRAF; the disease is melanoma.